Status:

TERMINATED

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Lead Sponsor:

Actelion

Conditions:

Pulmonary Hypertension

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"

Eligibility Criteria

Inclusion

  • Male or female, aged 18-85 years
  • Have a current diagnosis of symptomatic pulmonary arterial hypertension (PAH) classified by one of the following: a) idiopathic pulmonary arterial hypertension (IPAH) or familial pulmonary arterial hypertension (FPAH); b) PAH associated with one of the following connective tissue diseases and mild or no lung parenchymal disease: scleroderma spectrum of disease, systemic lupus erythematosis, or mixed connective tissue disease, c) PAH associated with repaired atrial septal defect (ASD), ventricular septal defect (VSD), or patent ductus arteriosis (PDA) ≥ 1 year post-operative from Screening, d) PAH associated with human immunodeficiency virus (HIV), or e) PAH associated with the use of anorexigens (e.g. fenfluramine-phentermine)
  • On a stable and well tolerated dose regimen of Ventavis (5 μg per dose) for at least 4 weeks prior to the Screening visit, using the I-neb AAD System equipped with Power Disc-6

Exclusion

  • Receipt of any prostacyclin or prostacyclin analogue other than Ventavis within the 12 weeks preceding the Screening visit
  • Receipt of atrial septostomy within the 6 months preceding Screening
  • History of left-sided heart disease
  • Clinically relevant obstructive lung disease
  • Chronic renal or liver disease
  • Uncontrolled systemic hypertension or hypotension
  • Cerebrovascular event within the 6 months preceding Screening

Key Trial Info

Start Date :

September 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT00467896

Start Date

September 1 2006

End Date

June 1 2011

Last Update

April 4 2013

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Pulmonary Associates

Phoenix, Arizona, United States, 85006

2

UCSD Medical Center, Thorton Hospital

La Jolla, California, United States, 92037

3

University of Iowa Hospital and Clinics

Iowa City, Iowa, United States, 52242

4

Ochsner Clinic Foundation

New Orleans, Louisiana, United States, 70112

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting | DecenTrialz